Therapeutic | Ublituximab |
Target | MS4A1 |
Heavy Chain | QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGGIYPGNGDTSYNQKFKGKATLTVGKSSSTAYMQLSSLTSEDSAVYFCARYDYNYAMDYWGQGTSVTVSS |
Light Chain | QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPARFSGSGSGTSYSFTISRVEAEDAATYYCQQWTFNPPTFGGGTRLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (August '23) | Phase-III |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | EMABling Platform |
INN Year Proposed | 2010 |
INN Year Recommended | 2011 |
Companies Involved | LFB Biotechnologies, rEVO Biologics, Johns Hopkins University, TG Therapeutics Inc |
Conditions Approved | na |
Conditions Active | Chronic lymphocytic leukaemia, Multiple sclerosis, Diffuse large B cell lymphoma, Follicular lymphoma, Mantle-cell lymphoma, Non-Hodgkin's lymphoma, Neuromyelitis optica |
Conditions Discontinued | na |
Notes | na |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]